Amylyx looks to cover financial gap left by Relyvrio with avexitide deal, says GlobalData GlobalData Jul 2, 2024 The acquisition is a strategic action by Amylyx following the failure of its lead amyotrophic lateral sclerosis (ALS) therapy,…
Amylyx’s efforts to explore other indications for Relyvrio seems to be bearing fruit: GlobalData EP News Bureau Jun 3, 2024 Amylyx explores new indications for Relyvrio after ALS trail setback, with early success in Wolfram syndrome and other…
